Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 CollaborationGlobeNewsWire • 12/19/22
Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, LecanemabPRNewsWire • 12/12/22
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)GlobeNewsWire • 12/09/22
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionBusiness Wire • 12/06/22
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALSGlobeNewsWire • 12/05/22
Biogen Inc. (BIIB) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript)Seeking Alpha • 12/02/22
5 things to know about the new Alzheimer's drug — including why it may be risky for people who take blood thinnersMarket Watch • 11/30/22